Diagnostic Value of Autoantibodies against Ezrin in Esophageal Squamous Cell Carcinoma

Abstract EN

Esophageal squamous cell carcinoma (ESCC), one of the most common malignancies worldwide, is a highly aggressive and homogeneous entity occurring in esophageal squamous epithelium, and a reliable noninvasive test for early detection is needed.

A recent study showed that serum autoantibodies against Ezrin could be detected in patients with pancreatic cancer.

Here, we assessed whether autoantibodies against Ezrin could have diagnostic relevance for early ESCC.

We analyzed autoantibodies against Ezrin in sera of 98 normal controls and 149 patients with ESCC.

Ezrin autoantibodies levels were evaluated by enzyme-linked immunosorbent assay (ELISA).

Results showed that higher levels of autoantibodies against Ezrin were observed in serum samples from patients with ESCC than in serum from normal controls ( P < 0.0001 ).

Based on a cutoff value of 0.319, the sensitivity and specificity of autoantibodies against Ezrin for diagnosis of ESCC were 27.5% and 95.9%, respectively.

Compared with normal controls, the positive rate of autoantibodies against Ezrin was significantly elevated in patients with early-stage ESCC ( P < 0.0001 ).

Moreover, there was no significant difference of positivity of autoantibodies against Ezrin in ESCC patients categorized according to age, gender, tumor size, tumor invasion depth, tumor site, histological grade, lymph node status, or tumor stage.

Our study indicates that the presence of autoantibodies against Ezrin is significantly associated with ESCC.